首页> 美国卫生研究院文献>Clinical Medicine Insights. Oncology >Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)

【2h】

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)

机译：免疫检查点抑制剂进展后转移性尿路上皮癌患者的临床结果：见面 - URO群体的回顾性分析（见URO 1研究）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Immune checkpoint inhibitors (ICIs) are currently the standard of care for metastatic urothelial cancer (mUC) after the failure of previous platinum-based chemotherapy. The choice of further therapy after ICI progression is a new challenge, and scarce data support it. We aimed to examine the outcomes of mUC patients after progression to ICI, especially when receiving chemotherapy.

机译：免疫检查点抑制剂（ICIS）是目前在先前铂化化疗失败后的转移性尿路上皮癌（MUC）的标准。在ICI进展后进一步治疗的选择是一个新的挑战，并且稀缺数据支持它。我们的旨在审查进程后对ICI后的MUC患者的结果，特别是在接受化疗时。

著录项

期刊名称 Clinical Medicine Insights. Oncology
作者
Melissa Bersanelli; Sebastiano Buti; Alessio Cortellini; Marco Bandini; Giuseppe Luigi Banna; Filippo Pederzoli; Elena Farè; Daniele Raggi; Patrizia Giannatempo; Ugo De Giorgi; Umberto Basso; Tania Losanno; Daniele Santini; Claudia Mucciarini; Marcello Tucci; Rosa Tambaro; Azzurra Farnesi; Orazio Caffo; Antonello Veccia; Emanuele Naglieri; Alberto Briganti; Giuseppe Procopio; Sandro Pignata; Andrea Necchi;
展开▼
作者单位

展开▼
年(卷),期 2021(-1),-1
年度 2021
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

机译：尿液癌;转移性尿路上皮癌;化疗;免疫检查点抑制剂;免疫疗法;

相似文献

外文文献
中文文献
专利

1. Outcomes of combination therapy with tyrosine kinase inhibitors and immune checkpoint inhibitors in metastatic renal cell carcinoma – A retrospective study [J] . Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners . 2020,第3期

机译：转移肾细胞癌中酪氨酸激酶抑制剂和免疫检查点抑制剂的联合治疗结果 - 回顾性研究
2. Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis [J] . Di Nunno Vincenzo, De Luca Emmanuele, Buttigliero Consuelo, Critical reviews in oncology/hematology . 2018,第期

机译：免疫检查点抑制剂在先前治疗的晚期或转移性尿路上皮癌的患者中：系统审查和荟萃分析
3. Clinical Outcomes, Costs, and Healthcare Resource Utilization in Patients with Metastatic Merkel Cell Carcinoma Treated with Immune Checkpoint Inhibitors vs Chemotherapy [J] . Ying Zheng, Ting Yu, Rachel H Mackey, ClinicoEconomics and Outcomes Research . 2021,第a期

机译：用免疫检查点抑制剂治疗的转移Merkel细胞癌患者患者的临床结果，成本和医疗资源利用率对化疗
4. CEREBRAL MICROBLEEDS IN DOGS: A RETROSPECTIVE STUDY OF DEMOGRAPHICS, CLINICAL ASSOCIATIONS AND PATIENT OUTCOME [C] . Sharon Kerwin, C. Elizabeth Boudreau, Christine Budke, Conference of the American^College^of^Veterinary^Internal^Medicine . 2016

机译：脑脊液中的脑脊布：人口统计学，临床关联和患者结果的回顾性研究
5. Clinical outcomes of patients with non-small cell lung carcinoma: a retrospective study. [D] . Decker, Brandee. 2013

机译：非小细胞肺癌患者的临床结局：一项回顾性研究。
6. Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b) [O] . Marco Stellato, Daniele Santini, Elena Verzoni, 2021

机译：肾切除术对免疫肿瘤学治疗的转移性肾癌临床结果的影响：代表遇见 - URO集团的真实研究（Meetureo-7B）
7. Immune Checkpoints Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials [O] . Hsiao-Ling Chen, Vinson Wai-Shun Chan, Yu-Kang Tu, 2021

机译：免疫检查点抑制剂和化疗作为转移性尿路上皮癌的一线治疗：随机期III临床试验的网络荟萃分析

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)

摘要

著录项

相似文献

相关主题

期刊订阅